Liposomal amphotericin b-review of clinical experience and future directions
Journal name: World Journal of Pharmaceutical Research
Original article title: Liposomal amphotericin b-review of clinical experience and future directions
The WJPR includes peer-reviewed publications such as scientific research papers, reports, review articles, company news, thesis reports and case studies in areas of Biology, Pharmaceutical industries and Chemical technology while incorporating ancient fields of knowledge such combining Ayurveda with scientific data.
This page presents a generated summary with additional references; See source (below) for actual content.
Original source:
This page is merely a summary which is automatically generated hence you should visit the source to read the original article which includes the author, publication date, notes and references.
Dr. Payal Preet and Dr. Anita K. Gupta
World Journal of Pharmaceutical Research:
(An ISO 9001:2015 Certified International Journal)
Full text available for: Liposomal amphotericin b-review of clinical experience and future directions
Source type: An International Peer Reviewed Journal for Pharmaceutical and Medical and Scientific Research
Doi: 10.20959/wjpr20177-8747
Copyright (license): WJPR: All rights reserved
Download the PDF file of the original publication
Summary of article contents:
1) Introduction
Liposomal amphotericin B (LAmB) is a lipid formulation of the polyene antifungal agent amphotericin B, primarily used to treat invasive fungal infections. This innovative formulation has gained significant traction due to its reduced toxicity compared to traditional amphotericin B deoxycholate (DAmB), especially in terms of nephrotoxicity and infusion-related reactions. LAmB maintains the antifungal properties of amphotericin B while minimizing adverse side effects, making it a standard treatment option for various medically important opportunistic fungal pathogens. Despite its widespread use in clinical practice, comprehensive understanding of its pharmacokinetics, appropriate dosing regimens, and potential clinical scenarios remains a topic of ongoing investigation.
2) Pharmacokinetics and Drug Delivery
The pharmacokinetic profile of LAmB is distinct, characterized by a significant volume of distribution and long terminal half-life. This formulation allows for sustained drug levels in tissues while minimizing systemic exposure, leading to lower rates of nephrotoxicity. LAmB is primarily delivered in intact liposomes, which facilitate selective distribution and reduce exposure to excretory pathways. Such properties suggest the potential feasibility of intermittent or single-dose regimens, which could provide clinical advantages by reducing treatment costs and the risk of adverse effects. These unique pharmacokinetics also pave the way for novel administration routes, including aerosolized therapies, that could enhance local delivery to the lungs.
3) Clinical Applications and Efficacy
LAmB is indicated in a variety of clinical scenarios, particularly for patients vulnerable to invasive fungal infections, such as those undergoing immunosuppressive therapy. Studies have shown its efficacy in treating conditions like cryptococcal meningitis, invasive candidiasis, and visceral leishmaniasis. In empirical therapy for febrile neutropenia, LAmB has demonstrated comparable efficacy to DAmB, with a significantly lower incidence of severe toxicity-related events. Its effectiveness against diverse fungal pathogens, in combination with its improved safety profile, reinforces its role as an essential antifungal agent in clinical settings, especially for high-risk patient populations.
4) Safety Profile and Toxicity
One of the pivotal features of LAmB is its improved safety compared to traditional formulations. While DAmB is associated with significant nephrotoxicity, infusion reactions, and potential hepatotoxicity, LAmB consistently shows a reduced incidence of these side effects. The encapsulation of amphotericin B within liposomes protects renal tissues from exposure to free drug, mitigating renal injury. Although some hepatotoxic effects have been observed, these are not dose-dependent and need further elucidation. Understanding these safety profiles is critical for optimizing LAmB use, especially in vulnerable populations like neonates and individuals with pre-existing conditions.
5) Conclusion
Liposomal amphotericin B represents a significant advancement in the treatment of invasive fungal infections, blending potent antifungal activity with a favorable safety profile. As LAmB continues to establish its place in clinical practice, ongoing research is vital to exploit its pharmacokinetic advantages, explore novel delivery methods, and clarify optimal dosing strategies tailored to special populations. Given the growing concerns over antifungal resistance and the limited availability of new therapeutic agents, maximizing the utility of LAmB could play a critical role in improving clinical outcomes and addressing the pressing issue of invasive fungal diseases in various patient groups.
FAQ section (important questions/answers):
What is liposomal amphotericin B (LAmB) used for?
Liposomal amphotericin B (LAmB) is primarily used to treat serious fungal infections, especially in immunocompromised patients, and is the standard of care for infections caused by opportunistic fungi.
How does LAmB differ from conventional amphotericin B deoxycholate?
LAmB has a significantly improved toxicity profile compared to conventional amphotericin B deoxycholate (DAmB). It causes less nephrotoxicity and has different pharmacokinetic properties, allowing it to be administered in different dosing strategies.
What are the reported advantages of using LAmB?
LAmB offers a reduced risk of nephrotoxicity, potentially allows for intermittent dosing, and it retains antifungal efficacy against a wide range of pathogens with fewer side effects.
Are there any specific clinical indications for LAmB?
Yes, LAmB is indicated for conditions such as febrile neutropenia, systemic aspergillosis, candidiasis, cryptococcal meningitis, and visceral leishmaniasis, particularly in patients at risk of renal toxicity.
What challenges exist for clinical trials involving LAmB?
Clinical trials for LAmB face challenges such as limited patient populations, the need for head-to-head comparison with existing therapies, and the lack of suitable alternative agents for mycoses.
What are the future directions for LAmB usage?
Future directions include investigating alternative administration routes like aerosolized therapy, catheter lock therapy, and optimizing dosing regimens for better efficacy and accessibility in resource-limited settings.
Glossary definitions and references:
Scientific and Ayurvedic Glossary list for “Liposomal amphotericin b-review of clinical experience and future directions”. This list explains important keywords that occur in this article and links it to the glossary for a better understanding of that concept in the context of Ayurveda and other topics.
1) Drug:
A substance that causes a physiological change in the body, often utilized in treatment for diseases. The review discusses liposomal amphotericin B as a drug, illustrating its efficacy and safety compared to conventional formulations, underpinning its critical role in managing invasive fungal infections in clinical settings.
2) Toxicity:
Refers to the degree to which a substance can cause harm to an organism. The article highlights the reduced toxicity profile of liposomal amphotericin B compared to conventional amphotericin B, emphasizing its importance in minimizing adverse drug effects while treating potentially lethal fungal infections.
3) Study (Studying):
The act of examining a subject in detail. The review emphasizes the importance of studying liposomal amphotericin B's pharmacokinetics and pharmacodynamics to optimize its clinical use and address gaps in knowledge regarding its administration in various patient populations.
4) Activity:
In pharmacology, it describes the effectiveness of a drug against pathogens. The review presents the antifungal activity of liposomal amphotericin B compared to traditional formulations, highlighting its potential role in treating various fungal infections, thus guiding treatment strategies in clinical practice.
5) Pharmacology:
The branch of medicine concerned with the uses, effects, and modes of action of drugs. In the context of the review, pharmacology is essential for understanding how liposomal amphotericin B functions differently than traditional amphotericin B, influencing treatment decisions for fungal infections.
6) Animal:
Living organisms used for research purposes. The paper references animal studies that illustrate the pharmacokinetics and efficacy of liposomal amphotericin B, essential for establishing performance and safety profiles before transitioning findings to human clinical trials.
7) Disease:
A disorder of a structure or function that produces specific symptoms. The review discusses various diseases, particularly invasive fungal infections, where liposomal amphotericin B is utilized, supporting its role in treating infections associated with significant morbidity and mortality.
8) Death:
The cessation of all biological functions that sustain a living organism. The review underscores the importance of effective treatment for invasive fungal infections, as inadequate treatment can lead to high mortality rates, emphasizing the critical role of liposomal amphotericin B in improving patient outcomes.
9) Antibiotic (Antibacterial):
Refers to drugs that inhibit bacterial growth. While the review focuses on antifungal treatments, the concept of antibacterial agents highlights the broader context of infection management in immunocompromised patients, where infections from multiple pathogens are a significant concern.
10) Wall:
Refers to the structural barrier surrounding cells, such as the fungal cell wall. The review describes how liposomal amphotericin B binds to fungal cell walls to exert its antifungal effects, being crucial to understanding its mechanism of action.
11) Life:
Refers to the condition of living organisms. The review discusses life-threatening infections like invasive fungal disease, emphasizing the need for effective treatments like liposomal amphotericin B to preserve life in at-risk patient populations.
12) Accumulation (Accumulating, Accumulate):
To gather or collect over time. In the context of the review, it refers to the accumulated evidence supporting the safety and efficacy of liposomal amphotericin B, which aids in clinical decision-making and encourages its adoption in treating fungal infections.
13) Discussion:
A detailed consideration or examination of a topic. The review contains multiple discussions concerning the pharmacokinetics, efficacy, and safety of liposomal amphotericin B, presenting insights that inform future research and clinical practices related to antifungal therapies.
14) Knowledge:
Information and skills acquired through experience or education. The review aims to enhance knowledge regarding liposomal amphotericin B and its use in treating fungal infections, ultimately contributing valuable insights to practitioners managing these clinical challenges.
15) Medicine:
A field focused on the diagnosis, treatment, and prevention of disease. The importance of medicine is highlighted in the review as it discusses advancements in antifungal treatments, specifically liposomal amphotericin B, and its impact on treating life-threatening infections.
16) Pregnant:
Refers to women carrying a developing fetus. The review notes the gaps in knowledge regarding the safety and efficacy of liposomal amphotericin B in special populations like pregnant women, indicating an essential area for future research considering their unique treatment needs.
17) Species:
A group of living organisms consisting of similar individuals capable of exchanging genes. The review refers to various fungal species affected by liposomal amphotericin B, providing context for its spectrum of activity and informing treatment decisions against specific pathogens.
18) Fever:
An elevation in body temperature, often a sign of infection. The review discusses how liposomal amphotericin B is used in patients with febrile neutropenia, highlighting its role in addressing potential fungal infections in immunocompromised individuals.
19) Bile:
A digestive fluid produced by the liver that aids in digestion. The review notes the limited urinary clearance and excretion of liposomal amphotericin B, indirectly referring to related bodily processes such as bile processing, emphasizing its pharmacokinetic properties.
20) Pain:
An unpleasant sensory or emotional experience associated with actual or potential tissue damage. The review mentions infusion-related pain as a side effect of liposomal amphotericin B, emphasizing the importance of monitoring and managing patient comfort during treatment.
21) Gold (Golden):
A valuable metal often used in various applications, including medical diagnostics. In the review, gold-labeled liposomes are mentioned, referring to studies that investigate the binding of liposomal formulations to fungal cells, underscoring innovative methods in drug delivery research.
22) Performance:
The ability to operate or function effectively. The review assesses the performance of liposomal amphotericin B in clinical scenarios, comparing it to traditional agents and emphasizing its efficacy and reduced toxicity as key performance indicators in its use.
23) Measurement:
The process of obtaining the magnitude of a quantity. In the context of the review, measurement is crucial for determining drug concentrations and pharmacokinetic properties, guiding dosage decisions and treatment plans for patients receiving liposomal amphotericin B.
24) Observation:
The action of monitoring or examining something. The review refers to numerous observations made during clinical studies of liposomal amphotericin B, contributing to the existing body of evidence regarding its safety and efficacy in treating fungal infections.
25) Relative:
Considered in relation to something else. The review discusses the relative safety and efficacy of liposomal amphotericin B compared to traditional formulations, informing clinicians about the importance of these factors in treatment selection for invasive fungal infections.
26) Writing:
The act of composing text for communication. The review is a piece of medical writing that consolidates research findings about liposomal amphotericin B, sharing knowledge with the broader medical community to enhance understanding and guide treatment practices.
27) Meeting:
An assembly of people to discuss a particular topic. The review suggests the need for meetings among clinical researchers and practitioners to discuss findings related to liposomal amphotericin B, fostering collaboration in advancing methodologies and improving patient care.
28) Account:
A report or description of an event or experience. The review presents an account of the clinical experience with liposomal amphotericin B, summarizing findings from studies and guiding practitioners' understanding of its role in antifungal therapy.
29) Reason:
A cause or explanation for an action or event. The review addresses the reasons behind the development of liposomal amphotericin B—primarily to reduce toxicity and improve efficacy compared to traditional formulations, influencing clinical choices for treating fungal infections.
30) Gupta:
A surname common in India, potentially linking to the review's author, Dr. Anita K. Gupta, who contributes expertise to the examination of liposomal amphotericin B. This author's involvement emphasizes the collaborative nature of the research presented in the review.
31) India:
A country in South Asia, associated with significant healthcare challenges, including infectious diseases. The review acknowledges the context in which liposomal amphotericin B may be particularly relevant, given the country's burden of fungal infections, contributing to a global understanding of treatment needs.
32) Blood:
A bodily fluid that transports nutrients and oxygen. The review touches upon blood parameters indirectly via pharmacokinetics of liposomal amphotericin B, including how the drug interacts with blood proteins, which may influence its effectiveness and safety for patients.
33) Hand:
The end part of a person's arm, often associated with the act of touching or holding. The review metaphorically implies the 'hand' of the clinician in decision-making processes regarding the use of liposomal amphotericin B, framing the human element in medical care.
34) Shand (Sand):
A granular material often used as a metaphor for resource limitations in the context of leishmaniasis endemic areas. The review implies challenges faced in treating infections in resource-poor settings where liposomal amphotericin B’s cost remains a critical issue for access to care.
35) Pur:
Lacking sufficient money to meet basic living expenses. The review emphasizes issues faced by populations in resource-poor settings, highlighting how the cost of liposomal amphotericin B affects accessibility, thus influencing treatment outcomes for fungal infections in vulnerable communities.
Other Science Concepts:
Discover the significance of concepts within the article: ‘Liposomal amphotericin b-review of clinical experience and future directions’. Further sources in the context of Science might help you critically compare this page with similair documents:
Pharmacological properties, Clinical trial, Hepatotoxicity, Toxicity profile, Pharmacokinetics and pharmacodynamics, Nephrotoxicity, FDA approval, Liposomal amphotericin B.